Squarepoint Ops LLC Cassava Sciences Inc Transaction History

Squarepoint Ops LLC

$99.2 Billion
Q4 2024

A detailed history of Squarepoint Ops LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Squarepoint Ops LLC holds 54,090 shares of SAVA stock, worth $137,929. This represents 0.0% of its overall portfolio holdings.

Number of Shares

54,090

Previous 10,333 423.47%

Holding current value

$137,929

Previous $304,000 58.22%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$2.29 - $32.18 $100,203 - $1.41 Million	43,757 Added 423.47%	54,090 $127,000
Q3 2024 Nov 14, 2024	BUY	$9.57 - $35.08 $98,886 - $362,481	10,333 New	10,333 $304,000
Q2 2023 Aug 14, 2023	BUY	$21.59 - $27.88 $707,180 - $913,209	32,755 New	32,755 $803,000
Q3 2022 Nov 14, 2022	BUY	$16.33 - $51.06 $342,848 - $1.07 Million	20,995 New	20,995 $878,000
Q2 2022 Aug 15, 2022	SELL	$17.22 - $38.47 $243,473 - $543,927	-14,139 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$32.6 - $53.05 $460,931 - $750,073	14,139 New	14,139 $525,000
Q4 2021 Feb 14, 2022	SELL	$36.77 - $90.91 $1.34 Million - $3.31 Million	-36,405 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$41.79 - $135.3 $1.24 Million - $4.02 Million	29,710 Added 443.76%	36,405 $2.26 Million
Q2 2021 Aug 16, 2021	SELL	$32.15 - $89.72 $1.45 Million - $4.05 Million	-45,090 Reduced 87.07%	6,695 $572,000
Q1 2021 May 17, 2021	SELL	$7.09 - $87.95 $332,946 - $4.13 Million	-46,960 Reduced 47.56%	51,785 $2.33 Million
Q4 2020 Feb 16, 2021	BUY	$6.79 - $12.25 $670,478 - $1.21 Million	98,745 New	98,745 $673,000
Q3 2020 Nov 16, 2020	SELL	$2.86 - $11.51 $53,064 - $213,556	-18,554 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$2.04 - $9.64 $37,850 - $178,860	18,554 New	18,554 $57,000

Others Institutions Holding SAVA

# of Institutions

190

Shares Held

16.4M

Call Options Held

3.49M

Put Options Held

8.08M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $102M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.

Account

Squarepoint Ops LLC Cassava Sciences Inc Transaction History